Get started
Author

Bev Parker

Abstract P6-10-02: Assessing biomarkers to inform treatment de-escalation: Mid-treatment biopsy cellularity predicts pCR in the I-SPY 2 Trial
2020 · Sara J Venters, Denise M Wolf, et al. · Cancer Research · 4
Advocate involvement in Clinical Trials: Lessons from the Patient-centric I-SPY2 Breast Cancer Trial
2023 · Jane Perlmutter, Susie Brain, et al. · Medical Research Archives · 3
PDF
Abstract P5-07-03: The Association Between Symptom Severity and Physical Function among Participants in I-SPY2
2023 · Amrita Basu, Saumya Umashankar, et al. · Cancer Research
Abstract P4-12-02: Improving patient-reported outcome data capture for clinical research: ePRO in ISPY 2, a phase 2 breast cancer study
2022 · Anna Northrop, Anika Christofferson, et al. · Cancer Research
Abstract PS11-08: Operational standardization and quality assurance yield high acceptance rate for breast MRI in the I-SPY 2 TRIAL
2021 · Jessica Gibbs, David C Newitt, et al. · Cancer Research
Abstract P3-08-16: The impact of residual ductal carcinoma in situ on breast cancer recurrence in the neoadjuvant I-SPY2 TRIAL
2020 · Marie Osdoit, Christina Yau, et al. · Cancer Research
Bridging Research and Clinical Care: Real-Time ePRO Adverse Event Real-Time Reporting in a Phase II Breast Cancer Study.
2019 · Adam L. Asare, Smita Asare, et al. · AMIA
Works count: 7
Citation count: 7
H-index: 2
I10-index:
Year
Topic
Type